News

Published on 15 Nov 2023 on GuruFocus.com via Yahoo Finance

RAPT Therapeutics Inc Reports Increased R&D Expenses Amid Progress in Clinical Trials

Article preview image

Net loss for Q3 2023 expanded to $31.4 million from $21.2 million in Q3 2022.Research and development expenses rose significantly due to higher development costs for zelnecirnon.Company maintains a robust cash position of $184.8 million, expecting to fund operations through mid-2025.Top-line data from Phase 2b trial of zelnecirnon in atopic dermatitis expected in mid-2024.

Warning! GuruFocus has detected 2 Warning Sign with RAPT.

Read the rest of the article
NASDAQ.RAPT price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
RAPT Therapeutics, Inc. (RAPT) Stock Falls Following FDA Setback; Short Sellers...

We recently published a list of 15 Worst 52-Week Low Stocks to Buy Now According to Short Sellers...

Insider Monkey · via Yahoo Finance 24 Sep 2024
Should You Sell Your Stake in RAPT Therapeutics (RAPT)?

TimesSquare Capital Management, an equity investment management company, released its “U.S. Small...

Insider Monkey · via Yahoo Finance 20 Jun 2024
What's Going On With Dermatitis-Focused RAPT Therapeutics Stock On Thursday?

What's Going On With Dermatitis-Focused RAPT Therapeutics Stock On Thursday? On Thursday, RAPT Th...

Benzinga via Yahoo Finance 9 May 2024
What Makes RAPT Therapeutics (RAPT) an Investment Choice?

TimesSquare Capital Management, an equity investment management company, released its “U.S. Small...

Insider Monkey via Yahoo Finance 22 Mar 2024
Should You Buy RAPT Therapeutics (RAPT) Ahead of Earnings?

Investors are always looking for stocks that are poised to beat at earnings season and RAPT Thera...

Zacks via Yahoo Finance 7 Mar 2024
The Zacks Analyst Blog Highlights Moderna, RAPT Therapeutics, Iovance, Sarepta Therapeutics and...

For Immediate Release Chicago, IL – February 23, 2024 – Zacks.com announces the list of stocks fe...

Zacks via Yahoo Finance 23 Feb 2024
Insider Buyers Lose Additional US$63k As RAPT Therapeutics Dips To US$236m

The recent price decline of 73% in RAPT Therapeutics, Inc.'s (NASDAQ:RAPT) stock may have disappo...

Simply Wall St. via Yahoo Finance 21 Feb 2024
What's Going On With RAPT Therapeutics Stock On Wednesday? - RAPT Therapeutics (NASDAQ:RAPT)

Tuesday, the FDA verbally notified RAPT Therapeutics Inc RAPT that a clinical hold has been place...

Benzinga 21 Feb 2024
FDA halts RAPT Therapeutics trials due to liver failure case

The U.S. Food and Drug Administration (FDA) has verbally informed the company of a hold on its Ph...

Investing.com 20 Feb 2024
RAPT Therapeutics Inc Reports Increased R&D Expenses Amid Progress in Clinical Trials

<img src=https://s.yimg.com/ny/api/res/1.2/OJolqZFB5GvM9xdrGNUkFg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2O...

GuruFocus.com via Yahoo Finance 15 Nov 2023

Copyright Statfolio @ 2024

Social Accounts